(5-(3-thienyl)tetrazol-1-yl)acetic-acid and propionylcarnitine

The effects of propionyl-L-carnitine (PCAL) on caudal motor nerve conduction velocity, the coefficient of variation of the R-R interval on the electrocardiogram, and sciatic nerve blood flow were compared with those of [5-(3-thienyl)tetrazol-1-yl] acetic acid monohydrate, an aldose reductase inhibitor, in rats with streptozotocin-induced diabetes. Diabetic control rats showed significantly delayed nerve conduction (P < .05), decreased R-R variability (P < .05) and reduced sciatic nerve blood flow (P < .05). Oral administration of PCAL (0.5 g/kg/day) and [5-(3-thienyl)tetrazol-1-yl] acetic acid monohydrate (0.05% in the diet: 60 mg/kg/day) for 8 weeks significantly improved both nerve conduction (P < .05) and R-R variability (P < .05) in diabetic rats, along with the normalization of sciatic nerve blood flow. PCAL treatment increased the nerve tissue levels of carnitine and myo-inositol and reduced the serum triglyceride level in diabetic rats. Our results suggests that PCAL could have therapeutic potential for the treatment of diabetic neuropathy.

Topics: Aldehyde Reductase; Animals; Blood Glucose; Body Weight; Carbohydrate Metabolism; Cardiotonic Agents; Carnitine; Cauda Equina; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Electrocardiography; Enzyme Inhibitors; Heart Conduction System; Lipids; Male; Motor Neurons; Neural Conduction; Rats; Rats, Wistar; Sciatic Nerve; Tetrazoles; Thiophenes